Innovent Biologics, Inc. (HKEX: 01801) announced Wednesday that the agreement with Eli Lilly and Company (NYSE: LLY) on global expansion collaboration of TYVYT® now becomes effective immediately.
The biopharmaceutical company said in today’s announcement that TYVYT® is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.
The sintilimab injection “has been granted marketing approval by the NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy,” said Innovent.
Founded in 2011, Innovent develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited On October 31, 2018.
Shares of Innovent closed at HK$59.4 on Wednesday, down 1.9%.